<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Syre on Finance Insights Daily</title><link>https://finance.dpfeed.com/tags/syre/</link><description>Recent content in Syre on Finance Insights Daily</description><image><title>Finance Insights Daily</title><url>https://finance.dpfeed.com/images/finance-insights-og.jpg</url><link>https://finance.dpfeed.com/images/finance-insights-og.jpg</link></image><generator>Hugo -- 0.147.7</generator><language>en-us</language><lastBuildDate>Tue, 14 Apr 2026 07:01:10 +0000</lastBuildDate><atom:link href="https://finance.dpfeed.com/tags/syre/index.xml" rel="self" type="application/rss+xml"/><item><title>Ulcerative Colitis Breakthrough: SPY001 Shows Promising SKYLINE Trial Results</title><link>https://finance.dpfeed.com/posts/ulcerative-colitis-breakthrough-spy001-shows-promising-skyline-trial-results/</link><pubDate>Tue, 14 Apr 2026 07:01:10 +0000</pubDate><guid>https://finance.dpfeed.com/posts/ulcerative-colitis-breakthrough-spy001-shows-promising-skyline-trial-results/</guid><description>Financial analysis and investment insights on Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-t</description></item></channel></rss>